Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies

References

• Badger C. C., Bernstein I. D. Therapy of murin leukaemia with monoclonal antibody against a norm; differentiation antigen. J. Exp. Med. 1983; 157: 828–842
   PubMed Web of Science ®Google Scholar
• Opitz H. G., Opitz U., Hewlett G., Schlumberger H. I. A new model for investigations of T cell function in mic Differential immunosuppressive effects of two monoclon; anit-Thy-1 antibodies. Immunobiol. 1982; 160: 438–453
   PubMed Web of Science ®Google Scholar
• Ritz J., Schlossman S. F. Utilization of monoclon; antibodies in the treatment of leukemia and lymphoma. Blood 1982; 59: 1–11
   PubMed Web of Science ®Google Scholar
• Levy R., Miller R. A. Biological and clinical implicatiot of lymphocyte hybridomas: tumor therapy with monoclon; antibodies. Ann. Rev. Med. 1983; 34: 107–127
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., Goldman C. K., Bongiovanni K., Sharrow S. O., Davey M. P., Cease K. B., Greenberg S., Longo D. L. Therapy of patients with human T-ce lymphotrophic virus-I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor f interleukin-2. Blood 1988; 72: 1805–1814
   PubMed Web of Science ®Google Scholar
• Fourth International Workshop on Leucocyte Differentiation Antigens, W. Knapp. Oxford University Press, Oxford 1990, in press
   Google Scholar
• Hale G., Bright S., Chumbley G., Hoang T., Metcalf D, Munro A.J., Waldmann H. Removal of T cells fro bone marrow for transplantation: a monoclonal antibody the fixes human complement. Blood 1983; 62: 873–880
   PubMed Web of Science ®Google Scholar
• Hale G., Swirsky D., Waldmann H., Chan L. C. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br. J. Haematol. 198?; 6: 41–47
   Google Scholar
• Bindon C. I., Hale G., Waldmann H. Importance antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur. J. Immunol. 1988; 18: 1507–1514
   PubMed Web of Science ®Google Scholar
• Hale G., Cobbold S. P., Waldmann H., Easter Matejtschuk P., Coombs R. R. A. Isolation low-frequency class-switch variants from rat hybrid myeloma. J. Immunol. Methods 1987; 103: 59–67
   PubMed Web of Science ®Google Scholar
• Riechmann L., Clark M. R., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 198?; 322: 323–32
   Google Scholar
• Dyer M. J. S., Hale G., Hayhoe F. G. J., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 198?; 73: 1431–1439
   PubMed Web of Science ®Google Scholar
• Hale G., Dyer M. J. S., Clark M. R., Phillips J. M., Marcus R. E., Riechmann L., Winter G., Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody, CAMPATH-1H. Lancet 1988; 2: 1395–1401
   Google Scholar
• Dyer M. J. S. T-cell receptor S/a rearrangements in lymphoid neoplasms. Blood 1989; 74: 1073–1084
   PubMed Web of Science ®Google Scholar
• Mack D., Couzens S., Reardon D., Marcus R. E. A three-stage immunophenotyping technique for rapid diagnosis of haematological malignancies. Br. J. Haematol. 1988; 69: 137
   Web of Science ®Google Scholar
• Dyer M. J. S., Fischer P., Nacheva E., Labastide W., Karpas A. A new human B-cell non-Hodgkin lymphoma cell line exhibiting both t(14;18) and t(4;11) chromosomal translocations. Blood 1990, (in press)
   PubMed Web of Science ®Google Scholar
• Bakhshi A., Wright J. J., Graninger W., Seto M., Cossman J., Jensen J. P., Goldman P., Korsmyer S. J. Mechanisms of t(14;18) translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc. Natl. Acad. Sci. USA 1987; 84: 2396–2401
   PubMed Web of Science ®Google Scholar
• Bertoli L. F., Kubagawa H., Borzillo G. V., Burrows P. D., Schreeder M. T., Carroll A. J., Cooper M. D. Bone marrow origin of a B-cell lymphoma. Blood 1988; 72: 94–102
   PubMed Web of Science ®Google Scholar
• Hale G., Swirsky D. M., Hayhoe F. G. J., Waldmann H. Effects of monoclonal antilymphocyte antibodies in vivo in monkeys and humans. Mol. Biol. Med. 1983; 1: 321–337
   PubMedGoogle Scholar
• Hale G., Clark M., Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J. Immunol 1985; 134: 3056–3065
   PubMedGoogle Scholar
• Bruggemann M., Williams G. T., Bindon C. I., Clark M. R., Walker M. R., Jefferis R., Waldmann H., Neuberger M. S. Comparison of the effector functions of human immunoglobulins using a matched set of chimaeric antibodies. J. Exp. Med 1987; 166: 1351–1361
   PubMed Web of Science ®Google Scholar
• Hamblin T. J., Cattan A. R., Glennie M. J., MacKenzie M. R., Stevenson F. R., Watts H. F., Stevenson G. T. Initial experiences in treating human lymphoma with a chimaeric univalent derivative of monoclonal anti-idiotype antibody. Blood 1987; 69: 790–797
   PubMed Web of Science ®Google Scholar
• Wing E. J., Magee D. M., Whiteside T. L., Kaplan S. S., Shadduck R. K. Recombinant human granulocyte/macrophage colony stimulating factor enhances monocyte cytotoxicity and secretion of tumour necrosis factor and interferon in cancer patients. Blood 1989; 73: 643–646
   PubMed Web of Science ®Google Scholar
• Hu E., Epstein A. L., Naeve G. S., Gill I., Martin S., Sherrod A., Nichols P., Chen D., Mazrunder A., Levine A. M. A phase la clinical trial of LYM-1 monoclonal antibody therapy in patients with refractory B-cell malignancies. Haematol. Oncol. 1989; 7: 155–171
   Google Scholar
• Meeker T. C., Lowder J., Maloney D. G., Miller R. A., Thielmans K., Warnke R., Levy R. A clinical trial of anti-idiotype therapy for B-cell malignancy. Blood 1985; 65: 1349–1363
   PubMed Web of Science ®Google Scholar
• DeNardo S. J., DeNardo G. L., O'Grady L. F., Hu E., Sybsma V. H., Mills S. L., Levy N. B., Macey D. J., Miller C. H., Epstein A. L. Treatment of B-cell malignancies with I113-LYM-1 monoclonal antibodies. Int. J. Cancer 1988; 3: 96–103
   Google Scholar
• Press O. W., Eary J. F., Badger C. C., Martin P. J., Appelbaum F. R., Levy R., Miller R., Brown S., Nelp W. B., Krohn K. A., Fisher D., Desantes K., Porter B., Kidd P., Thomas E. D., Bernstein I. D. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (CD37) antibody. J. Clin. Oncol. 1989; 7: 1027–1048
   PubMed Web of Science ®Google Scholar
• Farber S., Diamond L. K., Mercer R. D., Sylvester R. F., Wolff J. A. Temporary remissions in acute leukaemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (Aminoptenn). New Engl J. Med. 1948; 238: 787–793
   PubMed Web of Science ®Google Scholar
• Bindon C. I., Hale G., Clark M., Waldmann H. Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement mediated lysis. Transplantation 1985; 40: 538–544
   PubMed Web of Science ®Google Scholar